Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2663-2667

  Kuragano, Takahiro ^a   Itoh, Katsukiyo ^a   Shimonaka, Yasushi ^b   Kida, Aritoshi ^a   Furuta, Minoru ^a   Kitamura, Rie ^a   Yahiro, Mana ^a   Nanami, Masayohi ^a   Otaki, Yoshinaga ^a   Hasuike, Yukiko ^a   Nonoguchi, Hiroshi ^a   Nakanishi, Takeshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

hemodialysis; hepcidin; iron metabolism; TNF ; vascular stiffness

Indexed keywords

CHOLESTEROL; HEPCIDIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPCIDIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; INTERLEUKIN 6 BLOOD LEVEL; IRON METABOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RISK ASSESSMENT; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL;

ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PULSATILE FLOW; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 79961065890     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq760     Document Type: Article

References (22)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-S119 (Pubitemid 28527268)
2. Sullivan JL. Iron in arterial plaque: a modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-723
3. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093 (Pubitemid 40007660)
4. Dunn LL, Rahmanto YS, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol 2007;17:93-100 (Pubitemid 46199183)
5. Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995;75:519-560
6. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327
7. Yambe M, Tomiyama H, Hirayama Y et al. Arterial stiffness as a possible risk factor for both atherosclerosis and diastolic heart failure. Hypertens Res 2004;27:625-631 (Pubitemid 39534503)
8. Kitahara T, Ono K, Tsuchida A et al. Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients. Am J Kidney Dis 2005;46:688-696 (Pubitemid 41383947)
9. Kuragano T, Shimonaka Y, Kida A et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol 2010;31:534-540
10. Murao N, Ishigai M, Yasuno H et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/ selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007;21:4033-4038
11. Cheng L-T, Tang L-J, Chen H-M et al. Relationship between serum albumin and pulse velocity in patients on continuous ambulatory dialysis. Vasc Health Risk Manag 2008;4:871-876
12. Jung JY, Hwang YH, Lee SW et al. Factors associated with aortic stiffness and its change over time in peritoneal dialysis patients. Nephrol Dial Transplant 2010;25:4041-4048
13. Nanami M, Ookawara T, Otaki Y et al. Tumor necrosis factoralpha-induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25:2495-2501 (Pubitemid 43732269)
14. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003;41(3 Suppl 1):S80-S83 (Pubitemid 36278352)
15. Van Lenten BJ, Prieve J, Navab M et al. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995;95:2104-2110
16. Matthews AJ, Vercellotti GM, Menchaca HJ et al. Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1). J Surg Res 1997;73:35-40 (Pubitemid 28068315)
17. Porreca E, Ucchino S, Di Febbo C et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994;14:299-304
18. Drüeke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end stage renal disease. Circulation 2002;106:2212-2217 (Pubitemid 35222215)
19. Reis KA, Guz G, Ozdemir H et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease. Int Heart J 2005;46:255-264
20. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004;24:949-954 (Pubitemid 38620877)
21. Tintut Y, Patel J, Parhami F et al. Tumor necrosis factor-a promotes in vitro calcification of vascular cells via the camp pathway. Circulation 2000;102:2636-2642
22. Tsirpanlis G. Is inflammation the link between atherosclerosis and vascular calcification in chronic kidney disease? Blood Purif 2007;25:179-182 (Pubitemid 46447077)